Skip to Content
Merck
  • [The prevention of the development of the collagen-induced microembolic syndrome by decreasing the hydrodynamic resistance of the blood with special polymers under flow].

[The prevention of the development of the collagen-induced microembolic syndrome by decreasing the hydrodynamic resistance of the blood with special polymers under flow].

Patologicheskaia fiziologiia i eksperimental'naia terapiia (1991-07-01)
I L Konorova, S E Akopov, E S Gabrielian, I V Gannushkina
ABSTRACT

The search for antiaggregatory compounds is undertaken, as a rule, under in vitro conditions which do not reflect the dynamics of the real process. The present work deals with study of the peculiarities of the development of the collagen induced microembolic syndrome and the effect produced on it by hydrodynamic resistance reducing polymers under conditions modelling real circulation. The authors show the formation of a developed microembolic syndrome under the effect of collagen with accumulation of vasoconstrictors in the environment and increase of red cell hemolysis. Reduction of blood flow turbulence by the addition of solutions of neutral high-molecular linear polymers revealed the inhibiting effect of these polymers on the development of intracellular aggregate formation and concomitant red cell microhemolysis, which was attended by sharp reduction of thromboxane A2 production in the experiment. The authors show the significance of hemodynamic conditions in the development of the microembolic syndrome and the possibility of preventing it under conditions of modification of the blood flow with polymers, which may be of high prophylactic importance.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Kollisolv® PEG E 400
Sigma-Aldrich
Kollisolv® PEG E 300
Supelco
Polyethylene glycol/Polyethylene oxide ReadyCal Set Mp ~250 -1′100 000, analytical standard
Sigma-Aldrich
Polyethylene glycol/ dimethyl sulfoxide solution, Hybri-Max, average mol wt 1,450, 50 % (w/v), 0.2 μm filtered, BioReagent, suitable for hybridoma
Sigma-Aldrich
Poly(ethylene glycol), BioUltra, 400
Sigma-Aldrich
Poly(ethylene glycol), BioUltra, 1,500
Sigma-Aldrich
Poly(ethylene glycol), BioUltra, 4,000
Sigma-Aldrich
Poly(ethylene glycol), average Mn 600, waxy solid (moist)
Sigma-Aldrich
Poly(ethylene glycol), average Mn 3,350, powder
Supelco
Poly(ethylene glycol), analytical standard, for GPC, 40,000
Sigma-Aldrich
Poly(ethylene glycol), BioUltra, 3,350
Sigma-Aldrich
Poly(ethylene glycol), BioUltra, 3,000
Sigma-Aldrich
Poly(ethylene glycol), BioUltra, 35,000
Sigma-Aldrich
Poly(ethylene glycol), BioUltra, 2,000
Sigma-Aldrich
Poly(ethylene glycol), BioUltra, for molecular biology, 1,000
Sigma-Aldrich
Poly(ethylene glycol), BioUltra, 600
Sigma-Aldrich
Poly(ethylene glycol), BioUltra, 1,000
Sigma-Aldrich
Poly(ethylene glycol), BioUltra, 300
Supelco
Poly(ethylene glycol), analytical standard, for GPC, 108,000
Sigma-Aldrich
Poly(ethylene glycol), average Mn 20,000
Sigma-Aldrich
Poly(ethylene glycol), BioUltra, 8,000
Sigma-Aldrich
Poly(ethylene glycol), average Mw 1,500
Sigma-Aldrich
Poly(ethylene oxide), average Mv ~4,000,000 (nominal), contains <1000 ppm BHT as inhibitor
Sigma-Aldrich
Poly(ethylene oxide), average Mv 400,000 (nominal), powder
Sigma-Aldrich
Poly(ethylene oxide), average Mv ~900,000 (nominal), powder
Sigma-Aldrich
Poly(ethylene oxide), average Mv ~8,000,000 (nominal), powder
Sigma-Aldrich
Poly(ethylene oxide), average Mv ~2,000,000 (nominal), powder
Sigma-Aldrich
Poly(ethylene oxide), average Mv 200,000 (nominal), powder
Sigma-Aldrich
Poly(ethylene oxide), average Mv ~5,000,000 (nominal), powder
Sigma-Aldrich
Poly(ethylene glycol), average Mn 4,000, platelets